Progress of enhancing the function of chimeric antigen receptor T-cells in replased/refractory B-cell malignancies
10.3760/cma.j.cn115356-20201225-00319
- VernacularTitle:增强嵌合抗原受体T细胞功能在复发难治B细胞恶性肿瘤治疗中的研究进展
- Author:
Guoxing ZHAO
1
;
Zhi CHENG
;
Runhong WEI
Author Information
1. 河南省中医院（河南中医药大学第二附属医院）血液科 河南中医药大学血液病研究所，郑州 450002
- Keywords:
Chimeric antigen receptor T-cell;
B cell malignancies;
Recurrence;
Refractory;
Lenalidomide;
Decitabine;
Ibrutinib;
Programmed death 1 inhibitors
- From:
Journal of Leukemia & Lymphoma
2021;30(8):508-512
- CountryChina
- Language:Chinese
-
Abstract:
When chimeric antigen receptor T cells (CAR-T) failed to treat relapsed and refractory B-cell malignancies, some researchers try to improve the efficacy by enhancing the function of CAR-T. It is a new hotspot of drug development and clinical research, and significant achievements have been made in this area recently. Multi-targeted CAR-T, lenalidomide, decitabine, programmed death 1 inhibitor and ibrutinib can all enhance the function of CAR-T. This article reviews the recent progress of enhancing the function of CAR-T in relapsed and refractory B-cell malignancies.
